OptiNose Inc (NASDAQ:OPTN) insider Thomas Edward Gibbs bought 2,000 shares of the company’s stock in a transaction dated Wednesday, August 15th. The stock was purchased at an average cost of $12.69 per share, for a total transaction of $25,380.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of OPTN stock traded down $0.40 during trading on Wednesday, hitting $13.45. 44,809 shares of the company were exchanged, compared to its average volume of 182,721. The company has a debt-to-equity ratio of 0.57, a quick ratio of 9.50 and a current ratio of 9.66. The stock has a market cap of $797.38 million and a P/E ratio of -2.29. OptiNose Inc has a twelve month low of $12.51 and a twelve month high of $30.00.
OptiNose (NASDAQ:OPTN) last posted its quarterly earnings results on Tuesday, August 14th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.13. The company had revenue of $1.27 million for the quarter, compared to analyst estimates of $1.01 million. sell-side analysts predict that OptiNose Inc will post -3.15 EPS for the current year.
Hedge funds have recently bought and sold shares of the stock. Thompson Davis & CO. Inc. acquired a new stake in shares of OptiNose during the second quarter worth approximately $105,000. Summit Trail Advisors LLC acquired a new stake in shares of OptiNose during the second quarter worth approximately $109,000. TIAA CREF Investment Management LLC acquired a new stake in shares of OptiNose during the fourth quarter worth approximately $173,000. Teachers Advisors LLC acquired a new stake in shares of OptiNose during the fourth quarter worth approximately $184,000. Finally, Millennium Management LLC acquired a new stake in shares of OptiNose during the fourth quarter worth approximately $190,000. Institutional investors and hedge funds own 31.20% of the company’s stock.
OptiNose Company Profile
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Featured Article: Price to Earnings Ratio (PE)
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.